Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 17.3% in December
Biofrontera Inc. (NASDAQ:BFRI – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 467,400 share
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersBellerophon Therapeutics (NASDAQ:BLPH) shares increased by 18.4% to $2.9 during Wednesday's after-market session. This security traded at a volume of 416.2K shares come close, making up 40.3% o
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersShuttle Pharmaceuticals (NASDAQ:SHPH) stock rose 17.5% to $2.08 during Thursday's after-market session. At the close, Shuttle Pharmaceuticals's trading volume reached 565.4K shares. This is 40.
Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
05:30 PM EST, 01/09/2023 (MT Newswires) -- Biofrontera Inc. (BFRI), a dermatological products group, said it dosed its first patient in a phase-3 multicenter study evaluating the treatment of actinic
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first
Biofrontera Inc. Sees Prelim. Q4 Revenue $102.M-$10.4M
Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021. T
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, u
Biofrontera (NASDAQ:BFRI) Trading Down 1.1%
Biofrontera Inc. (NASDAQ:BFRI – Get Rating) fell 1.1% on Monday . The stock traded as low as $0.91 and last traded at $0.93. 3,094 shares were traded during mid-day trading, a decline of 100% from t
Biofrontera's Return On Capital Employed Overview
Benzinga Pro data, Biofrontera (NASDAQ:BFRI) reported Q3 sales of $4.32 million. Earnings fell to a loss of $2.57 million, resulting in a 201.88% decrease from last quarter. In Q2, Biofrontera brought
Biofrontera Has Received A Notice Of Allowance For Its U.S. Patent Application 17/269,816 Titled "Photodynamic Therapy Comprising Two Light Exposures At Different Wavelengths (For The Prevention Or Treatment Of Dermatological Disease)"
Biofrontera Has Received A Notice Of Allowance For Its U.S. Patent Application 17/269,816 Titled "Photodynamic Therapy Comprising Two Light Exposures At Different Wavelengths (For The Prevention Or Tr
Loading...
No Stock Yet